Last reviewed · How we verify
Magnesium isoglycyrrhizinate
At a glance
| Generic name | Magnesium isoglycyrrhizinate |
|---|---|
| Also known as | Magnesium Isoglycyrrhizinate Injection, Magnesium Isoglycyrrhizinate Injection Placebo, Tianqingganmei®, 2005S07127 |
| Sponsor | General Hospital of Shenyang Military Region |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia (NA)
- The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine (PHASE4)
- A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）
- Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury (PHASE4)
- Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B (PHASE4)
- Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury (PHASE2)
- Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury (PHASE4)
- A Study Evaluating the Efficacy of Glucocorticoids in Patients With Pre-ACLF-HBV (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: